The European Commission estimates that the European Union suffers a financial loss of around 1.5 billion euros a year because of antimicrobial resistance (AMR) related healthcare costs and productivity losses. Opening the single market more effectively would help reduce the grip of traditional chemical cleaning companies and allow for new hygiene technologies which can potentially reverse Europe’s critical AMR trend. The auditors will examine how the European Commission and relevant agencies manage the key activities and resources in this domain. They will also assess the relevance and effectiveness of EU contributions and support. Each year in the EU, infections caused by drug-resistant bacteria lead to the death of about 33,000 people and result in economic losses of around €1.5 billion. The World Bank has warned that, by 2050, such infections could cause as much global economic damage as the 2008 financial crisis.


The fight against “superbugs” in favor of health

“We believe Europe needs to quickly and massively upscale its fight against superbugs,” said Mario Pinca, iIntensive research has proven that COPMA’s hygiene system ‘PCHS’ can lead to a significant decrease of Healthcare Associated Infections. Research by Professors Elisabetta Caselli reports a 70 – 99.9% reduction of the main antibiotic resistance genes and a 76% reduction in the total antibiotic therapy cost.” Caselli’s team sampled 11,842 patients and tested 24,875 environmental samples to prove that an eco-sustainable probiotic detergent solutions-based cleaning system called ‘PCHS’ (Probiotic Cleaning Hygiene System) can stabilise surface pathogens, without selecting antibiotic-resistant species. The aim of the study was to determine whether PCHS application could impact on Healthcare Associated Infections (HAI) incidence. “The outstanding results could have a major life-saving impact, and a sustainable cost-saving for healthcare budgets,” said Pinca.



Everything is reduced related to our health

  1. 70 / 99.9% reduction of the main antibiotic resistance genes.
  2. 76% reduction in the total cost of antibiotic therapy.
  3. 61% reduction in the consumption of antimicrobial drugs
  4. 52% reduction in Healthcare Asociated infections.
  5. Reduction of 70/96% of pathogens compared to traditional methods.
  6. Reduction of 15/20% of direct production costs compared to traditional methods.
  7. Reduction of 29/33% of electricity and water consumption.
  8. 45% reduction of chemicals.
  9. Reduction of 35% of the carbon footprint
  10. .